Retatrutide

In participants with BMI ≥30 or 27-30 with weight-related conditions, retatrutide up to 8mg weekly led to mean weight reductions of up to 17.5% at 24 weeks and 24.2% at 48 weeks, with improvements in cardiometabolic markers.

Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.

Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.

In participants with BMI ≥30 or 27-30 with weight-related conditions, retatrutide up to 8mg weekly led to mean weight reductions of up to 17.5% at 24 weeks and 24.2% at 48 weeks, with improvements in cardiometabolic markers.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.

Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.

Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.

Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.

Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.